This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (47) Citing Articles via Google Scholar Google Scholar Articles by Applegate, R. J. Articles by Little, W. C. Search for Related Content PubMed PubMed Citation Articles by Applegate, R. J. Articles by Little, W. C. Related Collections Related Articles

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

"Off-Label" Stent Therapy

2-Year Comparison of Drug-Eluting Versus Bare-Metal Stents

Section of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

Manuscript received June 8, 2007; revised manuscript received August 17, 2007, accepted August 20, 2007.

^_* Reprint requests and correspondence: Dr. Robert J. Applegate, Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1045. (Email: bapplega{at}wfubmc.edu).

Objective: The aim was to compare 2-year outcomes with the routine use of drug-eluting stents (DES) (>75% "off-label") with a comparable group treated with bare-metal stents (BMS).

Background: Safety concerns >1 year from implantation have been raised about DES used "off-label." There are limited data comparing DES and BMS in "off-label" patients.

Methods: Clinical outcomes (nonfatal myocardial infarction [MI], all-cause mortality) were assessed in 1,164 consecutive patients who received BMS in the year before introduction of DES at Wake Forest University Baptist Medical Center and 1,285 consecutive patients who received DES after it became our routine choice. "On-label" stent use was defined as treatment for a single de novo lesion <30 mm, without recent MI or other major illnesses.

Results: At 2 years, the hazard ratio for DES compared with BMS for nonfatal MI or death was 0.77 (95% confidence interval [CI] 0.62 to 0.95), for all-cause mortality 0.71 (0.54 to 0.92), and stent thrombosis (ST) 0.97 (0.49 to 1.91). "On-label" stent procedures were associated with lower risk of MI, death, and ST than "off-label" stent procedures. For "off-label" stent procedures, the hazard ratio for DES compared with BMS for nonfatal MI or death was 0.78 (95% CI 0.62 to 0.98), all-cause mortality 0.72 (0.54 to 0.94), and ST 0.91 (0.46 to 1.80). The hazard of nonfatal MI or death was similar or lower for DES than BMS in high-risk subgroups, including renal failure and recent MI.

Conclusions: The routine clinical use of drug-eluting stents for "off-label" indications was associated with lower nonfatal MI and death at 2 years than in a comparable group of patients treated with BMS.

Abbreviations and Acronyms   ARC = Academic Research Consortium   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   HR = hazard ratio   MI = myocardial infarction   ST = stent thrombosis

Related Articles

Off-Label Use of Drug-Eluting Stents: Putting it in Perspective

Cindy L. Grines
J. Am. Coll. Cardiol. 2008 51: 615-617. [Full Text] [PDF]

This article has been cited by other articles:

				D. P. Ceppa, I. J. Welsby, T. Y. Wang, M. W. Onaitis, B. C. Tong, D. H. Harpole, T. A. D'Amico, and M. F. Berry Perioperative Management of Patients on Clopidogrel (Plavix) Undergoing Major Lung Resection Ann. Thorac. Surg., December 1, 2011; 92(6): 1971 - 1976. [Abstract] [Full Text] [PDF]

				P. E. Schafer, M. T. Sacrinty, D. J. Cohen, M. A. Kutcher, S. K. Gandhi, R. M. Santos, W. C. Little, and R. J. Applegate Cost-Effectiveness of Drug-Eluting Stents Versus Bare Metal Stents in Clinical Practice Circ Cardiovasc Qual Outcomes, July 1, 2011; 4(4): 408 - 415. [Abstract] [Full Text] [PDF]

				G. G. Stefanini, P. W. Serruys, S. Silber, A. A. Khattab, R. J. van Geuns, G. Richardt, P. E. Buszman, H. Kelbaek, A. J. van Boven, S. H. Hofma, et al. The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents: A Substudy of the RESOLUTE All Comers Trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) J. Am. Coll. Cardiol., May 31, 2011; 57(22): 2221 - 2232. [Abstract] [Full Text] [PDF]

				Y. Otsuka, S. Ishiwata, T. Inada, H. Kanno, E. Kyo, Y. Hayashi, H. Fujita, and I. Michishita Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry Eur. Heart J., April 1, 2011; 32(7): 829 - 837. [Abstract] [Full Text] [PDF]

				R. J. Krone, S. V. Rao, D. Dai, H. V. Anderson, E. D. Peterson, M. A. Brown, R. G. Brindis, L. W. Klein, R. E. Shaw, W. S. Weintraub, et al. Acceptance, Panic, and Partial Recovery: The Pattern of Usage of Drug-Eluting Stents After Introduction in the U.S. (A Report From the American College of Cardiology/National Cardiovascular Data Registry) J. Am. Coll. Cardiol. Intv., September 1, 2010; 3(9): 902 - 910. [Abstract] [Full Text] [PDF]

				S. Garg and P. W. Serruys Coronary Stents: Current Status J. Am. Coll. Cardiol., August 31, 2010; 56(10_Suppl_S): S1 - S42. [Abstract] [Full Text] [PDF]

				S. Garg and P. W Serruys Drug-eluting stents: a reappraisal Heart, April 1, 2010; 96(7): 489 - 493. [Full Text] [PDF]

				D. E. Kandzari, A. Farb, and A. B. Boam Percutaneous Coronary Intervention in Perspective: Drug-Eluting Stents as a Model for Regulatory Review Circ Cardiovasc Interv, December 1, 2009; 2(6): 574 - 579. [Full Text] [PDF]

				A. Latib, L. Ferri, A. Ielasi, C. Godino, A. Chieffo, V. Magni, G. Bassanelli, A. S.P. Sharp, R. Gerber, I. Michev, et al. Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents J. Am. Coll. Cardiol. Intv., December 1, 2009; 2(12): 1219 - 1226. [Abstract] [Full Text] [PDF]

				C. Lotan, I. T. Meredith, L. Mauri, M. Liu, M. T. Rothman, and for the E-Five Investigators Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice: 12-Month Data From the E-Five Registry J. Am. Coll. Cardiol. Intv., December 1, 2009; 2(12): 1227 - 1235. [Abstract] [Full Text] [PDF]

				S. Cook and P. Wenaweser Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis Circ Cardiovasc Interv, August 1, 2009; 2(4): 273 - 276. [Full Text] [PDF]

				M. Gyongyosi, G. Christ, I. Lang, G. Kreiner, H. Sochor, P. Probst, T. Neunteufl, R. Badr-Eslam, S. Winkler, N. Nyolczas, et al. 2-Year Results of the AUTAX (Austrian Multivessel TAXUS-Stent) Registry: Beyond the SYNTAX (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery) Study J. Am. Coll. Cardiol. Intv., August 1, 2009; 2(8): 718 - 727. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				D. T. Ko, M. Chiu, H. Guo, P. C. Austin, R. Goeree, E. Cohen, M. Labinaz, and J. V. Tu Safety and Effectiveness of Drug-Eluting and Bare-Metal Stents for Patients With Off- and On-Label Indications J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1773 - 1782. [Abstract] [Full Text] [PDF]

				J. Carlsson, S. K. James, J. Lindback, F. Schersten, T. Nilsson, U. Stenestrand, B. Lagerqvist, and for the SCAAR (Swedish Coronary Angiography and An Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria J. Am. Coll. Cardiol., April 21, 2009; 53(16): 1389 - 1398. [Abstract] [Full Text] [PDF]

				M. H. Shishehbor, S. J. Filby, A. K. Chhatriwalla, R. D. Christofferson, A. Jain, S. R. Kapadia, A. M. Lincoff, D. L. Bhatt, and S. G. Ellis Impact of Drug-Eluting Versus Bare-Metal Stents on Mortality in Patients With Anemia J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 329 - 336. [Abstract] [Full Text] [PDF]

				R. J. Applegate, M. T. Sacrinty, M. A. Kutcher, R. M. Santos, S. K. Gandhi, and W. C. Little 3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 231 - 239. [Abstract] [Full Text] [PDF]

				Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes. Circ Cardiovasc Interv, February 1, 2009; 2(1): 35 - 42.

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008 J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C.H. Pell, I. R. Starkey, et al. Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study Circ Cardiovasc Interv, August 1, 2008; 1(1): 45 - 52. [Abstract] [Full Text] [PDF]

				R. L. Talbert Overview of advances in cardiovascular disease treatment and prevention: The evolving role of antiplatelet therapy Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S1 - S5. [Abstract] [Full Text] [PDF]

				M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, N. de Cesare, A. E. Rodriguez, M. Ferrario, R. Moreno, et al. Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial JAMA, April 16, 2008; 299(15): 1788 - 1799. [Abstract] [Full Text] [PDF]

				C. L. Grines Off-Label Use of Drug-Eluting Stents: Putting it in Perspective J. Am. Coll. Cardiol., February 12, 2008; 51(6): 615 - 617. [Full Text] [PDF]